A follow-up study on Guillain-Barre syndrome and validation of Brighton criteria
Background: Guillain-Barre syndrome (GBS) is the major cause of acute flaccid paralysis (AFP). Comprehensive classification and predictive measures need to be created for GBS. This study was conducted to evaluate GBS patients’ prognosis and Brighton criteria validity in Iranian population.
Methods: This retrospective cohort study was conducted using medical records of patients with GBS admitted to Ghaem Hospital, Mashhad, Iran. After collecting data from cerebrospinal fluid (CSF) analysis, nerve conduction studies, and clinical examinations, Brighton criteria and GBS disability scores were calculated. Patients ultimately received follow-up telephone calls after 15 to 45 months of admission, checking on one’s clinical status and the ability to walk independently. Data were analyzed using SPSS software.
Results: Patients were mostly men (78.0%) with the mean age of 48.58 years. GBS onset was reported more frequently in spring. According to Brighton criteria, 41.4%, 51.6%, and 7.0% of the patients were classified as levels 1, 2, and 4, respectively. For GBS disability score, 54.7%, 16.4%, 9.4%, and 6.2% of the patients had grades of 4, 3, 2, and 1, respectively. 37 patients (39.4%) restored the ability to walk within the first month, while 3 patients (3.2%) were unable to walk by the end of the second year. Significant relationship was observed between the ability of walking independently and GBS disability score (P < 0.001).
Conclusion: In the Iranian GBS population, less than half of the patients met level 1 of Brighton criteria and more than half of them reached the GBS disability score of 4, and walking ability was correlated to GBS disability score.
2. Oparah SS, Subramanian VA. Granular cell myoblastoma of the bronchus: Report of 2 cases and review of the literature. Ann Thorac Surg 1976; 22(2): 199-202.
3. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet 2016; 388(10045): 717-27.
4. Guillain G, Barre J, Strohl A. Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916. Ann Med Interne (Paris). 1999; 150(1): 24-32. [In French].
5. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979; 110(2): 105-23.
6. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978; 2(8093): 750-3.
7. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990; 27(Suppl): S21-S24.
8. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain 2014; 137(Pt 1): 33-43.
9. Bayat G, Boostani R, Salehi M. The investigation of outcome and prognosis of Guillain-Barre syndrome in Ghaem Hospital of Mashhad, in 2006 [MD Thesis]. Mashhad, Iran: Mashhad University in Medical Sciences; 2007. [In Persian].
10. Alter M. The epidemiology of Guillain-Barre syndrome. Ann Neurol 1990; 27(Suppl): S7-12.
11. Ansari B, Basiri K, Derakhshan Y, Kadkhodaei F, Okhovat AA. Epidemiology and clinical features of Guillain-Barre syndrome in Isfahan, Iran. Adv Biomed Res 2018; 7: 87.
12. Arami MA, Yazdchi M, Khandaghi R. Epidemiology and characteristics of Guillain-Barre syndrome in the northwest of Iran. Ann Saudi Med 2006; 26(1): 22-7.
13. Safari A, Borhani-Haghighi A, Heydari ST, Lankarani KB. Increased Guillain-Barre syndrome admissions in Shiraz, southern Iran. Iran J Neurol 2013; 12(1): 15-8.
14. Grapperon AM, Berro M, Salort-Campana E, Verschueren A, Delmont E, Attarian S. Guillain-Barre syndrome subtypes: A clinical electrophysiological study of 100 patients. Rev Neurol (Paris) 2019; 175(1-2): 73-80.
15. Barzegar M, Dastgiri S, Karegarmaher MH, Varshochiani A. Epidemiology of childhood Guillan-Barre syndrome in the north west of Iran. BMC Neurol 2007; 7: 22.
16. Yadegari S, Nafissi S, Kazemi N. Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome. Iran J Neurol 2014; 13(3): 138-43.
17. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barre syndrome: Clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 1998; 44(5): 780-8.
18. Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain-Barre syndrome subtype: Could a single study suffice? J Neurol Neurosurg Psychiatry 2015; 86(1): 115-9.
19. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2012; (7): CD002063.
20. Mateen FJ, Cornblath DR, Jafari H, Shinohara RT, Khandit D, Ahuja B, et al. Guillain-Barre Syndrome in India: Population-based validation of the Brighton criteria. Vaccine 2011; 29(52): 9697-701.
21. van der Maas NA, Kramer MA, Jacobs BC, van Soest EM, Dieleman JP, Kemmeren JM, et al. Guillain-Barre syndrome: Background incidence rates in The Netherlands. J Peripher Nerv Syst 2011; 16(3): 243-9.
22. Islam MB, Islam Z, Farzana KS, Sarker SK, Endtz HP, Mohammad QD, et al. Guillain-Barre syndrome in Bangladesh: Validation of Brighton criteria. J Peripher Nerv Syst 2016; 21(4): 345-51.